<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16754">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02061709</url>
  </required_header>
  <id_info>
    <org_study_id>TR006</org_study_id>
    <nct_id>NCT02061709</nct_id>
  </id_info>
  <brief_title>Evaluating the Efficacy of Ragweed-SPIRE Following Exposure to Ragweed Allergen in an Environmental Exposure Chamber</brief_title>
  <official_title>A Double-Blind, Randomised, Placebo-Controlled Study to Evaluate Three Dose Regimens of Ragweed-SPIRE in Ragweed Allergic Subjects Following Challenge With Ragweed Allergen in an Environmental Exposure Chamber</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Circassia Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adiga Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Circassia Limited</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Ragweed-SPIRE is safe and effective at
      reducing allergy symptoms in people who suffer from allergy to Ragweed pollen
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from Baseline in mean Total Rhinoconjunctivitis Symptom Score (TRSS)</measure>
    <time_frame>Between Baseline and approximately 25 weeks after randomisation</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean Total Rhinoconjunctivitis Symptom Score (TRSS) - all timepoints</measure>
    <time_frame>Between Baseline and approximately 25 weeks after randomisation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in mean Total Nasal Symptom Score (TNSS)</measure>
    <time_frame>Aproximately 25 weeks after randomisation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in mean Total Non Nasal Symptom Scores (TNNSS)</measure>
    <time_frame>Approximately 25 weeks after randomisation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and tolerability</measure>
    <time_frame>Approximately 28 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Ragweed-SPIRE 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ragweed SPIRE regimen 1 given 2 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ragweed-SPIRE 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ragweed-SPIRE regimen 2 given 2 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ragweed-SPIRE 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ragweed-SPIRE regimen 3 given 2 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given 2 weeks apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ragweed-SPIRE</intervention_name>
    <arm_group_label>Ragweed-SPIRE 1</arm_group_label>
    <arm_group_label>Ragweed-SPIRE 2</arm_group_label>
    <arm_group_label>Ragweed-SPIRE 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged 18-65 years.

          -  Reliable history consistent with moderate to severe rhinoconjunctivitis on exposure
             to ragweed for at least the previous two seasons.

          -  Minimum qualifying rhinoconjunctivitis symptom scores

          -  Ragweed-specific Immunoglobulin E (IgE) &gt; 0.70 kU/L.

        Exclusion Criteria:

          -  Subjects with a history of ragweed pollen induced asthma

          -  A history of anaphylaxis to ragweed allergen.

          -  FEV1 &lt; 80 % of predicted.

          -  Subjects who cannot tolerate Baseline Challenge in the EEC.

          -  Subjects for whom administration of epinephrine is contraindicated (e.g. subjects
             with acute or chronic symptomatic coronary heart disease or severe hypertension).

          -  History of immunopathological diseases (e.g. multiple sclerosis) that in the opinion
             of the Investigator or the Sponsor could interfere with the results obtained from the
             study.

          -  A history of severe drug allergy, severe angioedema or anaphylactic reaction to food.

          -  A history of any significant disease or disorder (e.g. cardiovascular, pulmonary,
             gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic,
             neoplastic/malignant, psychiatric, major physical impairment)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piyush Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inflamax Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kanata Allergy Services</name>
      <address>
        <city>Kanata</city>
        <state>Ontario</state>
        <zip>K2L 3C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KGK Synergize Inc</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inflamax Research</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L8P 0A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taunton Health Centre</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1H 7K4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Allergy Asthma Associates</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 2G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>February 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rhinoconjunctivitis</keyword>
  <keyword>Rhinitis</keyword>
  <keyword>Seasonal</keyword>
  <keyword>Ragweed</keyword>
  <keyword>Allergy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
    <mesh_term>Rhinitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
